Omeros Corp (OMER) Stock: What Does the Chart Say Tuesday?

The market has been down on Omeros Corp (OMER) stock recently. OMER gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Omeros Corp has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on OMER!

See Full OMER Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With OMER Stock Today?

Omeros Corp (OMER) stock is trading at $1.43 as of 10:02 AM on Tuesday, Oct 17, a loss of -$0.11, or -7.15% from the previous closing price of $1.54. The stock has traded between $1.21 and $1.50 so far today. Volume today is light. So far 493,975 shares have traded compared to average volume of 707,526 shares.

More About Omeros Corp

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Click Here to get the full Stock Report for Omeros Corp stock.